» Articles » PMID: 21614566

Gene Expression Profiling Assigns CHEK2 1100delC Breast Cancers to the Luminal Intrinsic Subtypes

Abstract

CHEK2 1100delC is a moderate-risk cancer susceptibility allele that confers a high breast cancer risk in a polygenic setting. Gene expression profiling of CHEK2 1100delC breast cancers may reveal clues to the nature of the polygenic CHEK2 model and its genes involved. Here, we report global gene expression profiles of a cohort of 155 familial breast cancers, including 26 CHEK2 1100delC mutant tumors. In line with previous work, all CHEK2 1100delC mutant tumors clustered among the hormone receptor-positive breast cancers. In the hormone receptor-positive subset, a 40-gene CHEK2 signature was subsequently defined that significantly associated with CHEK2 1100delC breast cancers. The identification of a CHEK2 gene signature implies an unexpected biological homogeneity among the CHEK2 1100delC breast cancers. In addition, all 26 CHEK2 1100delC tumors classified as luminal intrinsic subtype breast cancers, with 8 luminal A and 18 luminal B tumors. This biological make-up of CHEK2 1100delC breast cancers suggests that a relatively limited number of additional susceptibility alleles are involved in the polygenic CHEK2 model. Identification of these as-yet-unknown susceptibility alleles should be aided by clues from the 40-gene CHEK2 signature.

Citing Articles

Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.

Schwartz C, Khorsandi N, Blanco A, Mukhtar R, Chen Y, Krings G Breast Cancer Res Treat. 2023; 204(1):171-179.

PMID: 38091153 PMC: 10806021. DOI: 10.1007/s10549-023-07176-8.


Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.

Smid M, Schmidt M, Prager-van der Smissen W, Ruigrok-Ritstier K, Schreurs M, Cornelissen S Breast Cancer Res. 2023; 25(1):53.

PMID: 37161532 PMC: 10169359. DOI: 10.1186/s13058-023-01653-0.


HER2-low breast cancer shows a lower immune response compared to HER2-negative cases.

van den Ende N, Smid M, Timmermans A, van Brakel J, Hansum T, Foekens R Sci Rep. 2022; 12(1):12974.

PMID: 35902644 PMC: 9334272. DOI: 10.1038/s41598-022-16898-6.


Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.

Iyevleva A, Aleksakhina S, Sokolenko A, Baskina S, Venina A, Anisimova E Breast Cancer Res Treat. 2022; 192(2):283-291.

PMID: 35020107 DOI: 10.1007/s10549-022-06517-3.


Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing.

Southey M, Dowty J, Riaz M, Steen J, Renault A, Tucker K NPJ Breast Cancer. 2021; 7(1):153.

PMID: 34887416 PMC: 8660783. DOI: 10.1038/s41523-021-00360-3.